- Theratechnologies Inc. (TH) reports its novel peptide-drug conjugates (PDCs) are effective in inhibiting vasculogenic mimicry (VM) in ovarian and triple negative breast cancer models
- The PDCs, TH1902 and TH1904, are derived from the company’s SORT1+ Technology
- SORT1 is a receptor that plays a significant role in protein internalization, sorting and trafficking
- These results further support the expectation that TH1902 and TH1904 may alter the VM process by bringing anticancer drugs, like docetaxel and doxorubicin, into SORT1-positive cancer cells
- Theratechnologies Inc. (TH) is down 1.595 per cent and is trading at $4.32 per share at 3:30 p.m. ET
Theratechnologies (TH) reports its investigational peptide-drug conjugates (PDCs) are effective in inhibiting vasculogenic mimicry (VM) in ovarian and breast cancer models.
VM is believed to be associated with tumour growth, resistance and poor prognosis in many types of aggressive cancers including ovarian and TNBC.
The PDCs, TH1902 and TH1904, are derived from the company’s SORT1+ Technology.
SORT1 is a receptor that plays a significant role in protein internalization, sorting and trafficking. It is highly expressed in cancer cells compared to healthy tissue making it an attractive target for cancer drug development.
According to Dr. Christian Marsolais, Senior Vice President and Chief Medical Officer, the results showcase [or the first time] the sortilin receptor plays a role in the formation of VM which is associated with cancer progression and resistance.
By targeting SORT1 the PDC’s have the potential to inhibit VM and cancer growth.
“This recognition by our scientific peers highlights the great potential of our PDCs as a unique and effective vehicle for the potential treatment of many types of cancers in which SORT1 receptors are overexpressed and provides additional evidence that SORT1 plays a major role in the generation of VM, particularly in TNBC and ovarian cancer,” said Dr. Marsolais.
These results further support the expectation that TH1902 and TH1904 may alter the VM process by bringing anticancer drugs, like docetaxel and doxorubicin, into SORT1-positive cancer cells.
Theratechnologies Inc. (TH) is down 1.595 per cent and is trading at $4.32 per share at 3:30 p.m. ET.
